Pfizer: From the Sales Pitch to the Copay Fund

Pfizer and its subsidiary Pharmacia & Upjohn agreed to a $2.3 billion package in the 2009 Pfizer pharmaceutical fraud settlement, which included civil allegations of off-label promotion and kickbacks. The civil cases followed the sales pitch through to government health care claims. A later Pfizer settlement followed a different route: donations that allegedly paid patients’ copays and generated Medicare-funded sales. For an insider, the connection is the business decision that turned a prescription into a government bill.

The Bextra Resolution Reached Beyond Bextra

Pfizer agreed to pay $1 billion under the civil False Claims Act within the broader package. The Justice Department’s September 2, 2009 announcement named Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. The civil allegations against Pfizer covered several products and ways of generating prescriptions.

Bextra was an anti-inflammatory drug that Pfizer withdrew from the market in 2005. The other drugs named in the civil promotion allegations were Geodon, an antipsychotic; Zyvox, an antibiotic; and Lyrica, an antiepileptic.

The civil settlement allocated $668,514,830 to the federal government and $331,485,170 to state Medicaid programs. Medicare, Medicaid and other government insurance programs were the payers affected. The announcement also described harm to TRICARE and postal employees receiving workers’ compensation.

At the time, the Justice Department described the package as the largest health care fraud settlement in its history. The alleged business model put taxpayers behind prescriptions for uses their programs did not cover.

What Is Considered Off-Label Promotion?

Off-label promotion means marketing a drug for a use outside the uses the Food and Drug Administration approved. Pfizer’s civil case connected that promotion to reimbursement: the government alleged that Pfizer caused claims for uses that were not medically accepted and therefore were not covered by the government programs billed.

The Justice Department said Pfizer promoted Bextra for uses and dosages that the Food and Drug Administration had specifically declined to approve because of safety concerns. The wider off-label promotion allegations reached all four named drugs.

For someone who worked in sales or medical communications, the useful connection is between the use being promoted and the use for which the government paid. Product materials and promotional instructions tell one part of that story. The resulting prescriptions and claims tell the other. That is the connection our whistleblower experts examine with you.

Neurontin Shows Why a Company Might Avoid Approval

Warner-Lambert’s Neurontin resolution, announced May 13, 2004, shows why a sales plan might point away from the approval process. The government said the company chose not to seek approval for new uses because it feared that approval would help generic competitors compete against a planned successor drug. Pfizer had become Warner-Lambert’s parent in 2000.

The government described promotion of Neurontin as the sole drug for epileptic seizures even after the Food and Drug Administration had specifically rejected that use. It also described paid consultants’ meetings where physicians provided little or no significant consulting, and planted audience questions at purportedly independent education events to offset unfavorable remarks about the drug.

Bextra, too, was promoted beyond an approval decision the agency had already made. An employee who knows the approval strategy may know why the sales instructions point elsewhere.

How Do Pharmaceutical Kickbacks Work?

In Pfizer’s civil settlement, the government alleged that payments to health care providers induced prescriptions of the named products and other drugs. The alleged pharmaceutical kickbacks bought influence over prescribing decisions that sent bills to government programs.

That gives the employee who knows provider payments a different view from the employee who knows the promotional materials. One may understand what a prescriber was told. Another may understand what the company paid to get the prescription. The civil case included both alleged routes to sales, with taxpayers paying the resulting claims.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the Pfizer resolution, the Justice Department said six whistleblowers would receive more than $102 million collectively from the federal share of the civil recovery.

Whistleblowers triggered the investigation by bringing qui tam cases.

The Pfizer Copay Settlement Followed a Different Route

Pfizer agreed to pay $23.85 million in the separate copay-foundation settlement announced on May 24, 2018. The government alleged that Pfizer used a purportedly independent charitable foundation to pay Medicare patients’ copays for Sutent, Inlyta and Tikosyn.

Here the alleged payment reached the patient through an intermediary. A Medicare-covered prescription can leave a patient owing a copayment, coinsurance or a deductible. The government explained that these patient contributions were intended partly to restrain healthcare costs, including the prices manufacturers could demand. Pfizer allegedly used charitable funding to remove that cost barrier while generating sales paid by Medicare.

Sutent and Inlyta Eligibility for Free Drugs Became Medicare Revenue

The government alleged that Pfizer worked with a third-party specialty pharmacy to move some Medicare patients who qualified for its free-drug program to foundation assistance instead. Sutent and Inlyta both treat renal cell carcinoma. Under the alleged arrangement, the foundation covered the patients’ Medicare copays, and filling their prescriptions generated Medicare claims.

According to the government’s allegations, the purpose was to generate revenue. Pfizer could have provided the drugs free to patients who qualified. By funding their copays through the foundation, it allegedly turned those prescriptions into sales at taxpayers’ expense.

The information traveled back as well. Pfizer allegedly donated to the foundation and then received data, through the specialty pharmacy, confirming that the foundation had funded Sutent and Inlyta patients’ copays. That detail connects the charitable donation to sales of the donor’s own products. A specialty-pharmacy employee could recognize the referral and the confirmation as parts of the same transaction.

The same relationship appeared in the United Therapeutics copay case. The government alleged that United Therapeutics routinely obtained foundation spending data for its drugs and used the information to decide how much to donate. It also alleged that the company excluded needy Medicare patients from its free-drug program. In both cases, the information returning to the manufacturer helped connect apparent charity to the manufacturer’s own sales.

Tikosyn’s Price Increase Came With a New Fund

According to the government, Pfizer raised the wholesale acquisition cost of a forty-capsule package of Tikosyn by 44% during the last three months of 2015. Tikosyn treats arrhythmia in patients with atrial fibrillation or atrial flutter. The government alleged that Pfizer coordinated a foundation fund’s opening with the price increase and financed the fund to cover the resulting patient need.

Wholesale acquisition cost is the manufacturer’s list price, before discounts and rebates. The price matters here because, according to the government, Pfizer knew the increase would raise Medicare patients’ copays and could leave more patients needing assistance.

The government alleged that Pfizer then referred Medicare patients who needed help with the increased copays to the foundation. According to that account, Tikosyn patients represented virtually all of the fund’s beneficiaries for the next nine months. A fund described by a medical condition was allegedly supporting almost exclusively the donor’s drug.

The distinction between list price and net revenue matters beyond this case. The USC Schaeffer Center’s 2020 study The Association Between Drug Rebates and List Prices found that rebates and list prices moved together for drugs without generic competition, leaving net prices relatively steady. The paper explains who bears the increase:

In Pfizer’s case, the government’s allegation brought the price decision and the assistance decision together. Pfizer allegedly raised the price, helped finance a fund for patients facing higher copays, and referred those patients to it. The alleged arrangement let the company address the patient’s immediate bill while keeping the higher price in place.

What Pfizer’s Compliance Agreements Were Meant to Watch

Both settlements brought corporate integrity agreements with the Department of Health and Human Services Office of Inspector General. The earlier agreement covered promotional conduct, and the later one covered third-party patient assistance. Both required compliance certifications from executives and board members, putting responsibility above the teams making the sales and assistance decisions.

Wyeth and Biohaven Show Other Routes to Government Claims

Wyeth and Pfizer agreed to pay $784.6 million in the Protonix Medicaid rebate settlement announced April 27, 2016. The government alleged that Wyeth bundled discounts on oral and intravenous Protonix to win hospital business, then hid those discounts from Medicaid and underpaid rebates. The commercial reason mattered: patients discharged on oral Protonix were likely to keep taking it, with payers including Medicaid paying nearly full price. A hospital discount could buy later sales while the reported price concealed what Medicaid was owed.

In the Biohaven settlement announced January 24, 2025, Pfizer agreed to pay $59,746,277 over alleged speaker-program payments to induce Nurtec ODT prescriptions. The alleged conduct preceded Pfizer’s acquisition of Biohaven, and Pfizer terminated the programs when it acquired the company. For someone who knows prescriber payments, the connection is between what the program paid for and the prescriptions it sought to generate.

What an Insider Can Connect

The Pfizer matters show how pharmaceutical whistleblowers can connect commercial decisions to government payments. The earlier allegations turn on promotional materials, instructions and provider payments. The later allegations turn on free-drug eligibility, specialty-pharmacy referrals, foundation spending data and the timing of a price increase and fund opening.

For an employee inside patient assistance, the telling detail may be that someone already qualified for free medicine before being moved into a program that generated Medicare claims. For an employee inside pricing, it may be the connection between a planned increase and the assistance arranged around it. For someone working with the specialty pharmacy, it may be the data showing whose prescriptions the donations funded.

Our work is to connect that view from inside the business to the payments and decisions it explains.

You Know How the Prescription Became a Sale

If you saw promotional instructions, provider payments or patient-assistance decisions drive government-funded prescriptions, speak to one of our whistleblower experts about how those prescriptions became government bills. We work alongside you to build the case and bring in pharmaceutical fraud whistleblower lawyers who understand promotion, copay funding and Medicare and Medicaid claims. You know how the business worked, and we bring the expertise and commitment to build your strongest pharmaceutical whistleblower case with you.